BioMarin Pharmaceutical Inc. announced positive results from more than three years of follow up from its ongoing global Phase 3 GENEr8-1 study of ROCTAVIANTMá(valoctocogene roxaparvovec), an investigational one-time gene therapy for the treatment of adults with severe hemophilia A. This is the large and longest global Phase 3 study to date for any gene therapy in hemophilia with 134 participants. P values for all primary and secondary endpoint comparisons were <0.001 and include the entire treatment period. In response to the U.S. Food and Drug Administration (FDA)'s request, and consistent with the FDA's guidance for other gene therapy trials for hemophilia, BioMarin has also analyzed annualized bleeding rate for all bleeds, regardless of whether those bleeds were treated with exogenous Factor VIII replacement.á Results from that analysis were similar to those reflected in the table above. In Year 3, the mean/median ABR for all bleeds was 1.4/0.0, and in Year 4 the mean/median ABR for all bleeds was 1.6/1.0. At the end of Year 3, 92% of patients remained off prophylaxis. Those patients who returned to Factor VIII or emicizumab prophylaxis did so safely.áBioMarin plans to present additional data from this study at upcoming medical meetings. Commercial Progress ináEurope: As the company has previously indicated, BioMarin is targeting outcomes-based agreements (OBAs) with the three large health insurance groups that represent about 80% of German lives. The company has executed an OBA with one of the three. The company expects to sign additional agreements in the coming weeks ináGermanyáand continues to progress the European launch of ROCTAVIAN on a country-by-country basis, including meetings with authorities ináFranceáand the submission of the reimbursement dossier ináItaly. For covered patients, the agreements provide for companion diagnostic testing and reimbursement of ROCTAVIAN, allowing physicians to prescribe and patients to be treated with therapy. The OBAs ináGermanyáare multiyear agreements that cover payer risk of patients potentially returning to prophylaxis through direct BioMarin financial commitment in return for substantial and full upfront payment. Valoctocogene Roxaparvovec Safety: Overall, to date, a single 6e13 vg/kg dose of valoctocogene roxaparvovec has been well tolerated with no delayed-onset treatment related adverse events (AEs). In Year 3, no new treatment-related serious adverse events or Grade 3 events attributed to valoctocogene roxaparvovec or corticosteroid use emerged. The most common AEs associated with valoctocogene roxaparvovec have occurred early and included transient infusion associated reactions and mild to moderate rise in liver enzymes with no long-lasting clinical sequelae. Alanine aminotransferase (ALT) elevation, a laboratory test of liver function, has remained the most common adverse drug reaction. Other adverse reactions have included aspartate aminotransferase (AST) elevation (101 participants, 63%), nausea (55 participants, 34%), headache (54 participants, 34%), and fatigue (44 participants, 28%). No participants have developed inhibitors to Factor VIII, thromboembolic events or malignancy associated with valoctocogene roxaparvovec. Regulatory Status:
These data will be shared with the FDA as part of the agency's ongoing review of the Biologics License Application (BLA) of ROCTAVIAN. The PDUFA date isáMarch 31, 2023, subject to possible agency extension. Additionally, the FDA completed a Pre-License Inspection of the manufacturing facility in early December.áBioMarin has provided responses to the comments and observations received at the close of the inspection, and the company believes all are addressable. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to valoctocogene roxaparvovec ináMarch 2021. RMAT is an expedited program intended to facilitate development and review of regenerative medicine therapies, such as valoctocogene roxaparvovec, that are expected to address an unmet medical need in patients with serious conditions. The RMAT designation is complementary to Breakthrough Therapy Designation, which the company received for valoctocogene roxaparvovec in 2017. In addition to the RMAT Designation and Breakthrough Therapy Designation, BioMarin's valoctocogene roxaparvovec also received orphan drug designation from the European Medicines Agency (EMA) and FDA for the treatment of severe hemophilia A. Orphan drug designation is reserved for medicines treating rare, life-threatening, or chronically debilitating diseases. The European Commission (EC) granted conditional marketing authorization to valoctocogene roxaparvovec gene therapy under the brand name ROCTAVIAN onáAugust 24, 2022. GENEr8-1 Study Description: The global Phase 3 GENEr8-1 study evaluates superiority of valoctocogene roxaparvovec at the 6e13 vg/kg dose compared to the current standard of care, FVIII prophylactic therapy.á All study participants had severe hemophilia A at baseline, defined as less than or equal to 1 IU/dL of Factor VIII activity.á The study included 134 total participants, all of whom had a minimum of 36 months of follow-up at the time of the data cut.á The first 22 participants were directly enrolled into the Phase 3 study, 17 of whom were HIV-negative and dosed at least 48 months or 4 years prior to the data cut date.á The remaining 112 participants (rollover population) completed at least six months in a separate non-interventional study to prospectively assess bleeding episodes, Factor VIII use, and health-related quality of life while receiving Factor VIII prophylaxis prior to rolling over to receive a single infusion of valoctocogene roxaparvovec in the GENEr8-1 study. Robust Clinical Program: BioMarin has multiple clinical studies underway in its comprehensive gene therapy program for the treatment of severe hemophilia A. In addition to the global Phase 3 study GENEr8-1 and the ongoing Phase 1/2 dose escalation study, the company is also conducting a Phase 3, single arm, open-label study to evaluate the efficacy and safety of valoctocogene roxaparvovec at a dose of 6e13 vg/kg with prophylactic corticosteroids in people with severe hemophilia A (Study 270-303). Also ongoing is a Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with severe hemophilia A with pre-existing AAV5 antibodies (Study 270-203) and a Phase 1/2 Study with the 6e13 vg/kg dose of valoctocogene roxaparvovec in people with severe hemophilia A with active or prior Factor VIII inhibitors (Study 270-205). About Hemophilia A: Hemophilia A, also called Factor VIII deficiency or classic hemophilia, is an X-linked genetic disorder caused by missing or defective Factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a new mutation that was not inherited. Approximately 1 in 10,000 people have hemophilia A.